Imaging Catheter for Heart Ablation Procedures
Part of Heart & circulation clinical trials.
This study tests a new imaging catheter (VERAFEYE) to help doctors guide ablation procedures for atrial flutter or atrial fibrillation. It may lead to safer, more precise treatment of these heart rhythm problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You are scheduled to have a catheter ablation (a procedure to fix irregular heartbeats) for atrial flutter or atrial fibrillation.
- You are willing to sign a consent form and follow the study schedule.
- You are not pregnant or planning to become pregnant during the study.
- You do not have any unhealed problems from a previous invasive procedure.
- You do not have a blood clot in your left atrium.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging system (VERAFEYE) that helps doctors guide catheter ablation, a procedure to fix irregular heartbeats like atrial fibrillation. It aims to see if the system makes the procedure safer or more effective.
This registry tracks how well the VERAFEYE system works for people having a procedure to treat atrial fibrillation (a type of irregular heartbeat) or to close the left atrial appendage. It helps doctors see if using this imaging tool during the procedure is safe and effective.
This study tests advanced technology to improve how atrial fibrillation (AFib) is treated with a heart ablation procedure. It may help patients who are already advised to have AFib ablation by seeing how well the approach works in real clinical practice.
This study tests a new device (FARAFLEX) that uses pulsed field energy to treat atrial fibrillation (AFib). You may qualify if you have persistent or paroxysmal AFib symptoms and have not had a prior ablation.
This trial tests a new catheter system to treat atrial fibrillation (AF) by creating small scars in the heart to block faulty signals. It may help people with symptoms that continue despite medication and who are scheduled for a standard ablation procedure.
This trial studies a heart procedure using the Affera SpherePVI system to treat paroxysmal (comes and goes) or persistent atrial fibrillation. It’s for people who still have symptoms despite at least one anti-arrhythmia medicine, and who are good candidates for catheter ablation.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.